J. Barrie Ward to Strengthen CRT’s Board of Directors
London, UK, 1 Aug 2006 – Cancer Research Technology Limited (CRT) today announced the appointment of Dr J. Barrie Ward as a Non-executive Director.
Dr Ward joins CRT’s Board of Directors with significant experience that will be invaluable as the company develops and commercialises therapeutic opportunities from CRT’s Development Laboratories and worldwide academic centres of excellence in drug discovery. Dr Ward’s experiences as Director of the Microbiology Division of Glaxo Research and Development Ltd., Chief Executive Officer of KuDOS Pharmaceuticals Ltd. and in his current positions as Chairman of the Board of Directors of AVANT Immunotherapeutics Inc. and Onyvax Ltd. relate to both biotherapeutics and small molecules and is well aligned with CRT’s broad development pipeline.
Furthermore Dr Ward’s previous position as Chairman of the Board of Directors and Chief Executive Officer of Virus Research Institute, Inc. will have an immediate benefit to the development and growth of CRT Inc., CRT’s new US subsidiary.
CRT also announced today that Dr Celia Caulcott is stepping down from the Board, having made significant contributions to the company during a period of unprecedented growth.
Dr Melanie Lee, Chairman of CRT, said, “We are delighted to appoint Barrie to the Board. His depth of knowledge and specific experience will greatly contribute to CRT's goal to improve the treatment and lives of cancer patients. We also thank Celia for her dedication and advice over the past years.”
---ends---
About Cancer Research Technology
Cancer Research Technology Limited (CRT) is an oncology-focused development and commercialisation company that realises cancer patient benefit from publicly- funded research worldwide. CRT works closely with leading international cancer scientists, their institutes and funding bodies to protect, develop and commercialise oncology-related discoveries. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found at www.cancertechnology.com.
|
